DexCom Inc. (DXCM): Price and Financial Metrics


DexCom Inc. (DXCM): $74.02

-1.43 (-1.90%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

DXCM POWR Grades


  • Quality is the dimension where DXCM ranks best; there it ranks ahead of 72.46% of US stocks.
  • DXCM's strongest trending metric is Stability; it's been moving down over the last 179 days.
  • DXCM's current lowest rank is in the Momentum metric (where it is better than 5.5% of US stocks).

DXCM Stock Summary

  • Dexcom Inc's market capitalization of $50,016,950,544 is ahead of 94.57% of US-listed equities.
  • DXCM's current price/earnings ratio is 323.32, which is higher than 98.13% of US stocks with positive earnings.
  • The price/operating cash flow metric for Dexcom Inc is higher than 96.12% of stocks in our set with a positive cash flow.
  • Stocks with similar financial metrics, market capitalization, and price volatility to Dexcom Inc are GLW, MCHP, BSY, TRMB, and KEYS.
  • DXCM's SEC filings can be seen here. And to visit Dexcom Inc's official web site, go to www.dexcom.com.

DXCM Valuation Summary

  • In comparison to the median Healthcare stock, DXCM's price/sales ratio is 107.93% higher, now standing at 23.6.
  • DXCM's price/sales ratio has moved NA NA over the prior 199 months.
  • Over the past 199 months, DXCM's EV/EBIT ratio has gone up 167.3.

Below are key valuation metrics over time for DXCM.

Stock Date P/S P/B P/E EV/EBIT
DXCM 2021-08-31 23.6 25.6 96.5 146.9
DXCM 2021-08-30 23.3 25.3 95.1 144.7
DXCM 2021-08-27 23.2 25.2 94.9 144.5
DXCM 2021-08-26 23.1 25.0 94.3 143.5
DXCM 2021-08-25 23.1 25.1 94.4 143.6
DXCM 2021-08-24 23.0 25.0 94.0 143.0

DXCM Growth Metrics

    Its year over year cash and equivalents growth rate is now at 25.52%.
  • Its 4 year price growth rate is now at 358.31%.
  • The year over year net income to common stockholders growth rate now stands at 247.53%.
DXCM's revenue has moved up $2,003,100,000 over the prior 70 months.

The table below shows DXCM's growth in key financial areas (numbers in millions of US dollars).

Date Revenue Operating Cash Flow Net Income to Common Stock
2021-12-31 2,448.5 442.5 154.7
2021-09-30 2,319.2 508.7 529.3
2021-06-30 2,169.9 409 530.6
2021-03-31 2,026.6 501.5 514
2020-12-31 1,926.7 475.6 493.6
2020-09-30 1,820.6 447.3 231.1

DXCM's Quality Factors

The “Quality” component of the POWR Ratings focuses on 31 different factors of a companies fundamentals and operational strength. Here are some key insights as we drill into the specifics of these quality attributes.
  • DXCM has a Quality Grade of B, ranking ahead of 87.89% of graded US stocks.
  • DXCM's asset turnover comes in at 0.517 -- ranking 89th of 186 Medical Equipment stocks.
  • VRAY, ZYXI, and SRTS are the stocks whose asset turnover ratios are most correlated with DXCM.

The table below shows DXCM's key quality metrics over time.

Period Asset Turnover Gross Margin ROIC
2021-09-30 0.517 0.693 0.081
2021-06-30 0.510 0.692 0.077
2021-03-31 0.506 0.675 0.070
2020-12-31 0.547 0.664 0.077
2020-09-30 0.597 0.654 0.089
2020-06-30 0.651 0.639 0.090

DXCM Price Target

For more insight on analysts targets of DXCM, see our DXCM price target page. And for a list of of all stocks sorted by upside potential based on analyst target price, see our Top Price Target page.

Average Price Target $530.60 Average Broker Recommendation 1.36 (Strong Buy)

DXCM Stock Price Chart Interactive Chart >

Price chart for DXCM

DXCM Price/Volume Stats

Current price $74.02 52-week high $164.86
Prev. close $75.45 52-week low $66.89
Day low $73.71 Volume 466,538
Day high $75.37 Avg. volume 3,578,244
50-day MA $82.94 Dividend yield N/A
200-day MA $116.52 Market Cap 29.05B

DexCom Inc. (DXCM) Company Bio


Dexcom was founded in 1999 by Scott Glenn, John Burd, Lauren Otsuki, Ellen Preston and Bret Megargel. In 2006, Dexcom received U.S. Food and Drug Administration (FDA) approval and launched the Dexcom STS Continuous Glucose Monitoring System, which is a three-day sensor that provides up to 288 glucose measurements for every 24 hours. Dexcom received approval of the second generation product, the Seven Continuous Glucose Monitoring System in May 2007. This device improved on accuracy and extended use from three to seven days. In 2008, Dexcom announced two consumer development agreements with Insulet Corporation and Animas Corporation as well as a development agreement with Edwards Lifesciences for a continuous glucose monitor in the intensive care unit hospital environment. (Source:Wikipedia)


DXCM Latest News Stream


Event/Time News Detail
Loading, please wait...

DXCM Latest Social Stream


Loading social stream, please wait...

View Full DXCM Social Stream

Latest DXCM News From Around the Web

Below are the latest news stories about Dexcom Inc that investors may wish to consider to help them evaluate DXCM as an investment opportunity.

Here’s Why Artisan Partners Trimmed its DexCom (DXCM) Position

Artisan Partners, a high value-added investment management firm, published its ‘Artisan Mid Cap Fund’ fourth quarter 2021 investor letter – a copy of which can be downloaded here.

Insider Monkey | February 25, 2022

Bull vs. Bear: DexCom Stock

Why are investors bullish on DexCom?

The Motley Fool | February 20, 2022

Dexcom Announces Upcoming Virtual Conference Presentations

SAN DIEGO, February 14, 2022--DexCom, Inc. (NASDAQ:DXCM) today announced that management will present an update on the company at the following upcoming virtual investor conferences:

Yahoo | February 14, 2022

DexCom Stock Falls As Q4 Profit, FY22 Sales Outlook Trail Wall Street Estimates

DexCom Inc''s (NASDAQ: DXCM ) Q4 adjusted EPS of $0.68 was lower than $0.91 posted a year ago and missing the consensus of $0.85. Sales increased 23% Y/Y to $698.2 million, surpassing the consensus of $695.63 million, and grew 20% on an organic basis. Volume growth and strong new customer additions Full story available on Benzinga.com

Benzinga | February 11, 2022

DexCom (DXCM) Q4 Earnings Miss, Revenues Beat Estimates

DexCom's (DXCM) fourth-quarter results benefit from domestic and international revenue growth and solid new customer additions.

Yahoo | February 11, 2022

Read More 'DXCM' Stories Here

DXCM Price Returns

1-mo -0.62%
3-mo -44.30%
6-mo -44.86%
1-year -30.66%
3-year 95.52%
5-year 304.76%
YTD -44.86%
2021 45.23%
2020 69.02%
2019 82.59%
2018 108.75%
2017 -3.87%

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!


Page generated in 0.5752 seconds.